Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorPeking Union Medical College Hospital
About this trial
The most common external beam radiotherapy fractionation scheme for cervical cancer is 45-50.4 Gy delivered in 25-28 fractions. However, prolonged treatment duration can lead to insufficient availability of medical resources. We hope to assess the safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with brachytherapy in patients with cervical cancer in a multicenter study.
Eligibility criteria
Qualifiers
The patient is fully voluntary and has the capacity for autonomy, signing the informed consent form 30 days prior to enrollment
Age ≥18 and ≤75 years
FIGO stage IB-IIIB cervical cancer; IIIC1 (lymph node metastasis ≤2 cm, without common iliac lymph node metastasis)
Pathologically diagnosed as squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
Disqualifiers
Patients who have undergone cervical cancer surgery, excluding pelvic lymphadenectomy or pelvic lymph node dissection, or cervical conization
FIGO stages IA, IIIC2, IVA, or IVB
FIGO stage IIIC1 with lymph nodes >2 cm, or with common iliac lymph node metastasis
History of prior abdominal or pelvic radiotherapy
Trial design
Treatments tested in this trial
- Moderated hypofractionated online adaptive radiotherapy
- Conventional radiotherapy
Treatment groups
440 Participants
are divided into 2 treatment groupsSponsors and collaborators
Peking Union Medical College Hospital
Lead sponsor
Peking University Cancer Hospital & Institute
Collaborator
Shandong Cancer Hospital and Institute
Collaborator
Ruijin Hospital
Collaborator
Source ClinicalTrials.gov